Combined Modality Approaches Using Vasculature-disrupting Agents

Vascular-Targeted Therapies in Oncology

Volumn , Issue , 2006, Pages 123-136

  Shi, Wenyin ^a,c   Horsman, Michael R ^b   Siemann, Dietmar W ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Combined modality approaches; Destroying existing tumor vasculature; Inhibiting tumor initiated angiogenic process; Tumor vasculature; Vascular disrupting agents (VDAs) DMXAA, CA4DP, ZD6126 and OXi4503; Vascular disrupting strategies; VDAs and antiangiogenic agents; VDAs and chemotherapy; VDAs and radiation therapy

Indexed keywords

EID: 33846204064     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470035439.ch7     Document Type: Chapter

References (71)

1. Blakey, D.C., Ashton, S.E., Westwood, F.R., Walker, M. and Ryan, A.J. (2002). ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54, 1497-1502.
2. Blakey, D.C., Westwood, F.R., Walker M, Hughes, G.D., Davis, P.D., Ashton, S.E. and Ryan, A.J. (2002). Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8, 1974-1983.
3. Brizel, D.M., Dodge, R.K., Clough, R.W. and Dewhirst, M.W. (1999). Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53, 113-117.
4. Brizel, D.M., Rosner, G.L., Harrelson, J., Prosnitz, L.R. and Dewhirst, M.W. (1994). Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30, 635-642.
5. Chaplin, D.J. and Dougherty, G.J. (1999). Tumor vasculature as a target for cancer therapy. Br J Cancer 80 (Suppl. 1), 57-64.
6. Chaplin, D.J., Pettit, G.R. and Hill, S.A. (1999). Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19, 189-195.
7. Ching, L.M., Joseph, W.R. and Baguley, B.C. (1992). Stimulation of macrophage tumoricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid. Biochem Pharmacol 44, 192-195.
8. Cliffe, S., Taylor, M.L., Rutland, M., Baguley, B.C., Hill, R.P. and Wilson, W.R. (1994). Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 29, 373-377.
9. Dark, G.G., Hill, S.A., Prise, V.E., Tozer, G.M., Pettit, G.R. and Chaplin, D.J. (1997). Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57, 1829-1834.
10. Denekamp, J. (1990). Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9, 267-282.
11. Denekamp, J. (1993). Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66, 181-196.
12. DeVita, V.T., Goldin, A. and Oliverio, V.T. et al. (1979). The drug development and clinical trials programs of the division of cancer treatment. Cancer Clin Trials 2, 195-216.
13. DeVita, V.T., Hellman, S. and Rosenberg, S. (1997). Cancer: Principles and Practice of Oncology. Lippincott-Raven, Philadelphia, PA.
14. Durand, R.E. (1991). Keynote address: the influence of microenvironmental factors on the activity of radiation and drugs. Int J Radiat Oncol Biol Phys 20, 253-258.
15. Feldmann, H.J., Molls, M. and Vaupel, P. (1999). Blood flow and oxygenation status of human tumors. Clinical investigations. Strahlenther Onkol 175, 1-9.
16. Folkman, J. (1995). Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333, 1757-1763.
17. Goto, H., Yano, S., Matsumori, Y., Ogawa, H., Blakey, D.C. and Sone, S. (2004). Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res 10, 7671-7676.
18. Grosios, K., Loadman, P.M., Swaine, D.J., Pettit, G.R. and Bibby, MC. (2000). Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20, 229-233.
19. Hill, S.A., Chaplin, D.J., Lewis, G. and Tozer, G.M. (2002). Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumor models. Int J Cancer 102, 70-74.
20. Hill, S.A., Toze, G.M., Pettit, G.R. and Chaplin, D.J. (2002). Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 22, 1453-1458.
21. Hori, K., Saito, S., Nihei, Y., Suzuki, M. and Sato, Y. (1999). Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Japan J Cancer Res 90, 1026-1038.
22. Hori, K., Saito, S., Sato, Y., Akita, H., Kawaguchi, T., Sugiyama, K. and Sato, H. (2003). Differential relationship between changes in tumor size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. Implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur J Cancer 39, 1957-1966.
23. Horsman, M.R., Ehrnrooth, E., Ladekarl, M. and Overgaard, J. (1998). The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 42, 895-898.
24. Horsman, M.R. and Murata, R. (2002). Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 54, 1518-1523.
25. Horsman, M.R. and Murata, R. (2003). Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57, 1047-1055.
26. Horsman, M.R., Murata, R., Breidahl, T., Nielsen, F.U., Maxwell, R.J., Stodkiled-Jorgensen, H. and Overgaard, J. (2000). Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 476, 311-323.
27. Hua, J., Sheng, Y., Pinney, K.G., Garner, C.M., Kane, R.R., Prezioso, J.A., Pettit, G.R., Chaplin, D.J. and Edvardsen, K. (2003). Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 23, 1433-1440.
28. Kim, S., Min, S.Y., Lee, S.K. and Cho, W.J. (2003). Comparative molecular field analysis study of stilbene derivatives active against A549 lung carcinoma. Chem Pharm Bull (Tokyo) 51, 516-521.
29. Knocke, T.H., Weitmann, H.D., Feldmann, H.J., Selzer, E. and Potter, R. (1999). Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 53, 99-104.
30. Landuyt, W., Ahmed, B., Nuyts, S., Theys, J., Op, d.B., Rijnders, A., Anne, J., van Oosterom, A., van den, B.W. and Lambin, P. (2001). In vivo antitumour effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49, 443-450.
31. Lash, C.J., Li, A.E., Rutland, M., Baguley, B.C., Zwi, L.J. and Wilson, W.R. (1998). Enhancement of the anti-tumor effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78, 439-445.
32. Laws, A.L., Matthew, A.M., Double, J.A. and Bibby, M.C. (1995). Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 71, 1204-1209.
33. Li, L., Rojiani, A.M. and Siemann, D.W. (1998). Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42, 899-903.
34. Li, L., Rojiani, A.M. and Siemann, D.W. (2002). Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol 41, 91-97.
35. Lozonschi, L., Sunamura, M., Kobari, M., Egawa, S., Ding, L. and Matsuno, S. (1999). Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59, 1252-1258.
36. Masunaga, S., Sakurai, Y., Suzuki, M., Nagata, K., Maruhashi, A., Kinash, Y. and Ono, K. (2004). Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy. Int J Radiat Oncol Biol Phys 60, 920-927.
37. Morinaga, Y., Suga, Y., Ehara, S., Harada, K., Nihei. Y. and Suzuki, M. (2003). Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 94, 200-204.
38. Murata, R., Overgaard, J. and Horsman, M.R. (2001). Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 51, 1018-1024.
39. Murata, R., Siemann, D.W., Overgaard, J. and Horsman, M.R. (2001). Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 156, 503-509.
40. Murata, R., Siemann, D.W., Overgaard, J. and Horsman, M.R. (2001). Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60, 155-161.
41. Nelkin, B.D. and Ball, D.W. (2001). Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 8, 157-160.
42. Nordsmark, M., Overgaard, M. and Overgaard, J. (1996). Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41, 31-39.
43. Okunieff, P., Hoeckel, M., Dunphy, E.P., Schlenger, K., Knoop, C. and Vaupel, P. (1993). Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 26, 631-636.
44. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H. and Folkman, J. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
45. Overgaard, J. and Horsman, M.R. (1996). Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6, 10-21.
46. Pedley, R.B., Boden, J.A., Boden, R., Boxer, G.M., Flynn, A.A., Keep, P.A. and Begent, R.H. (1996). Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 56, 3293-3300.
47. Pedley, R.B., El Emir, E., Flynn, A.A., Boxer, G.M., Dearling, J., Raleigh, J.A., Hill, S.A., Stuart, S., Motha, R. and Begent, R.H. (2002). Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys 54, 1524-1531.
48. Pedley, R.B., Hill, S.A., Boxer, G.M., Flynn, A.A., Boden, R., Watson, R., Dearling. J., Chaplin, D.J. and Begent, R.H. (2001). Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 61, 4716-4722.
49. Pedley, R.B., Sharma, S.K., Boxer, G.M., Boden, R., Stribbling, S.M., Davies L., Springer, C.J. and Begent, R.H. (1999). Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 59, 3998-4003.
50. Pruijn, F.B., van Daalen, M., Holford, N.H. and Wilson, W.R. (1997). Mechanisms of enhancement of the antitumour activity of melphalan by the tumor-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 39, 541-546.
51. Rewcastle, G.W., Atwell, G.J., Li, Z.A., Baguley, B.C. and Denny, W.A. (1991). Potential antitumour agent. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34, 217-222.
52. Rojiani, A.M., Li, L., Rise, L. and Siemann, D.W. (2002). Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol 41, 98-105.
53. Sartorelli, A.C. (1988). Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res 48, 775-778.
54. Shnyder, S.D., Cooper, P.A., Pettit, G.R., Lippert, J.W., III. and Bibby, M.C. (2003). Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res 23, 1619-1623.
55. Siemann, D.W. (1984). Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys 10, 1585-1594.
56. Siemann, D.W., Bibby, M.C., Dark, G.G., Dicker, A.P., Eskens, F.A., Horsman, M.R., Marme, D. and LoRusso, P.M. (2005). Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11, 416-420.
57. Siemann, D.W., Chaplin, D.J. and Horsman, M.R. (2004). Vascular-targeting therapies for treatment of malignant disease. Cancer 100, 2491-2499.
58. Siemann, D.W. and Horsman, M.R. (2004). Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Rev Anticancer Ther 4, 321-327.
59. Siemann, D.W., Mercer, E., Lepler, S. and Rojiani, A.M. (2002). Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99, 1-6.
60. Siemann, D.W. and Rojiani, A.M. (2002). Antitumour efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54, 1512-1517.
61. Siemann, D.W. and Rojiani, A.M. (2002). Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53, 164-171.
62. Siemann, D.W. and Shi, W. (2003). Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 13, 53-61.
63. Siim, B.G., Lee, A.E., Shalal-Zwain, S., Pruijn, F.B., McKeage, M.J. and Wilson, W.R. (2003). Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51, 43-52.
64. Souhami, R. and Tobias, J. (1986). Cancer and its Management. Blackwell, Oxford.
65. Thorpe, P.E. (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10, 415-427.
66. Tubiana, M. (1992). The role of local treatment in the cure of cancer. Eur J Cancer 28A: 2061-2069.
67. Vaupel, P., Kallinowski, P. and Okunieff, P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 46, 6449-6465.
68. Walenta, S., Schroeder, T. and Mueller-Klieser, W. (2002). Metabolic mapping with bioluminescence: basic and clinical relevance. Biomol Eng 18, 249-262.
69. Wedge, S.R., Kendrew, J., Ogilvie, D.J. et al. (2002). Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced anti-tumor response. Proc Am Assoc Cancer Res 43, 1081 [abstract].
70. Wilson, W.R., Li, A.E., Cowan, D.S. and Siim, B.G. (1998). Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42, 905-908.
71. Yoon, S.S., Eto, H., Lin, C.M., Nakamura, H., Pawlik, T.M., Song, S.U. and Tanabe, K.K. (1999). Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59, 6251-6256.